XIVOLRIS Trademark
Trademark Overview
On Thursday, July 21, 2022, a trademark application was filed for XIVOLRIS with the United States Patent and Trademark Office. The USPTO has given the XIVOLRIS trademark a serial number of 97514100. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, July 16, 2024. This trademark is owned by Clementia Pharmaceuticals Inc.. The XIVOLRIS trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutinin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin car...
General Information
| Serial Number | 97514100 |
| Word Mark | XIVOLRIS |
| Filing Date | Thursday, July 21, 2022 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Tuesday, July 16, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 19, 2023 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutinin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified component of the toxin haemagglutinin complex for skin care and the treatment of neurological disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 11, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Clementia Pharmaceuticals Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Montreal, Quebec H3B2V6
CA |
| Party Name | Clementia Pharmaceuticals Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Montreal, Quebec H3B4W5
CA |
Trademark Events
| Event Date | Event Description |
| Monday, July 25, 2022 | NEW APPLICATION ENTERED |
| Thursday, August 11, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, May 8, 2023 | ASSIGNED TO EXAMINER |
| Monday, May 15, 2023 | PRIORITY ACTION WRITTEN |
| Monday, May 15, 2023 | PRIORITY ACTION E-MAILED |
| Monday, May 15, 2023 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Wednesday, July 26, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, July 26, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Thursday, November 9, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, November 9, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, November 9, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, November 9, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 29, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 19, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 19, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, December 19, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 19, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, July 16, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, July 16, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, July 16, 2024 | SOU EXTENSION 1 GRANTED |
| Tuesday, July 16, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, November 15, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, December 19, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, February 13, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
